Funding for this research was provided by:
National Eye Institute (R01EY030283, R01EY024485)
Duke NIH Center Core Grant (EY005722)
Research to Prevent Blindness
Alcon
Eyegate
Kala
Novartis Pharmaceuticals Corporation
Trefoil
Quidel
Article History
Accepted: 30 November 2021
First Online: 19 April 2022
Declarations
:
: S.E.M: none, M.S: none, V.L.P: National Institutes of Health/National Eye Institute: R01EY030283 (Dr. Perez), R01EY024485 (Dr. Perez), Duke NIH Center Core Grant: EY005722 (Dr. Perez), and Duke Research to Prevent Blindness Unrestricted Grant (Dr. Perez), Alcon, Eyegate, Kala, Novartis, Trefoil, Quidel.